Printer Friendly

APROGENEX, INC. ANNOUNCES UNDERWRITER EXERCISE OF OPTION TO ACQUIRE AN ADDITIONAL 85,000 SHARES

 HOUSTON, Dec. 2 /PRNewswire/ -- Aprogenex, Inc. (AMEX: APG) today announced that the underwriters of its initial public offering have acquired an additional 85,000 shares of Common Stock pursuant to their over-allotment option, resulting in additional net proceeds to the company of approximately $671,000. The initial public offering was managed by H.J. Meyers & Co., Inc., and closed on Oct. 22, 1993 through the sale of 1,250,000 shares of Common Stock. After this sale, there are a total of 4,532,707 Common shares outstanding. The company's Common Stock is traded on The American Stock Exchange.
 Aprogenex develops and intends to manufacture and market diagnostic test systems based on its proprietary DNA probe technology to identify the presence or extent of genetic abnormalities and disease. Using a maternal blood sample, one of the company's products is designed to identify the rare fetal cells circulating within the mother's blood and to permit the diagnosis of up to 95 percent of prenatal genetic abnormalities, such as Down's Syndrome.
 -0- 12/2/93
 /CONTACT: Donald Payne, chief financial officer of Aprogenex, Inc., 713-748-5114/
 (APG)


CO: Aprogenex, Inc. ST: Texas IN: MTC SU:

JG -- NY088 -- 9892 12/02/93 14:36 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 1993
Words:201
Previous Article:DIGITAL AUDIO DISC CORPORATION CELEBRATES PRODUCTION OF 50 MILLIONTH CD-ROM DISC; MILESTONE IN DIGITAL OPTICAL MEDIA PRODUCTION
Next Article:PARIBAS DRIVS GARANTIS COUNTERPARTY RISK RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters